Overview

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Phase:
PHASE2
Details
Lead Sponsor:
Acumen Pharmaceuticals